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Immunoperoxidase el ctrophoresis was applied to the plasma of a patient showing a high level of prolactin 
(PRL) secreted by a pituitary adenoma. Two PRL monomers were detected with an anti-hPRL antiserum: 
a major 22 kDa form and a minor 25 kDa form. Concanavalin A-Sepharose 4B chromatography revealed 
that the 25 kDa form was a glycosylated variant of PRL. Incubation of this variant with endoglycosidase 
F led to its transformation into the 22 kDa form. 
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1. INTRODUCTION 
A glycosylated form of prolactin (GPRL) was 
isolated from ovine [l] and human pituitary glands 
[2]. This modified hormone presented a molecular 
mass near 25 kDa which was slightly higher than 
that of the major form (22 kDa). In addition, 
Sinha et al. [3] reported an uncharacterized 25 kDa 
form of PRL present in human plasma which, tak- 
ing its molecular mass into account, could corre- 
spond to the glycosylated variant. More recently, it 
was found that the human decidual tissue, in vitro, 
synthesized and released a glycosylated form of 
PRL [4]. Using ovine pituitaries, Strickland and 
Pierce [5] isolated a glycosylated form of PRL 
which was converted to monomeric PRL by diges- 
tion with endoglycosidase H, an enzyme that acts 
on high-mannose type oligosaccharides. 
Correspmdence address: J. Champier, Centre de 
MCdecine Nucltaire, Hapital Louis Pradel, F-69394 
Lyon Cedex 03, France 
Abbreviations: endo F, endo-/3-N-acetylglucosaminidase 
F; endo H, endo-B-N-acetylglucosaminidase H; GhPRL, 
glycosylated human prolactin; PRL, prolactin 
Here, we have taken advantage of the extreme 
sensitivity of a new technique, ‘immunoperoxidase 
electrophoresis’ (IPE) (i) to determine whether a 
glycosylated PRL variant could be observed in 
human plasma and (ii) to test the ability of specific 
endoglycosidases to deglycosylate this form. 
2. MATERIALS AND METHODS 
2.1. Origin of the plasma 
Plasma was taken from a patient presenting a 
prolactin-secreting pituitary invasive macroade- 
noma. The plasma PRL level, measured by a 
specific radioimmunoassay described in [6], was 
very elevated (~30 gg/ml; normal range 
< 25 ng/ml). 
2.2. Electrophoresis 
Polyacrylamide gel electrophoresis in the 
presence of dodecyl sulfate was carrkd out ac- 
cording to [7] with a 5% acrylamide concentration 
for the stacking gel and a 12% acrylamide concen- 
tration for the separating gel. Plasma was diluted 
in Laemmli sample buffer to obtain a concentra- 
tion of 1 mg protein/ml and heated for 5 min in a 
boiling water bath. 100 ~1 aliquots were applied in 
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duplicate to the top of a 130 x 200 x 2 mm gel in 
a Protean 2 slab cell (Biorad, Richmond, USA). 
Run time was between 4 and 5 h under constant 
current conditions (30 mA/gel). At the end of the 
migration, the gel was cut into two symmetrical 
parts. One part was stained with Coomassie 
brilliant blue, destained at room temperature in 
7% acetic acid and scanned for absorbance in a 
Vernon spectrophotodensitometer. The other part 
was submitted to electrotransfer. 
2.3. Electrotransfer 
The electrophoretic transfer of proteins from the 
gel to a nitrocellulose (NC) sheet with 0.2 /cm pores 
(Sartorius, Gottingen) was achieved as in [8] using 
a horizontal electrotransfer apparatus (Biolyon, 
Dardilly, France). Transfer was conducted at a 
constant voltage of 30 V for 90 min [9]. The NC 
sheet was saturated with 3% bovine serum albumin 
(BSA) in phosphate-buffered saline (PBS) for 
24 h. Protein fixation was then achieved in 4% 
PBS-buffered formaldehyde for 1 h and unoc- 
cupied protein-binding sites on the NC sheet were 
saturated with 0.05% Tween 20 in PBS for 1 h. 
2.4. Immunoperoxidase assay 
The NC sheet was incubated for 48 h at room 
temperature with anti-hPRL (prepared in our 
laboratory) at a dilution of 1: 500 in the presence 
of non-immune sheep serum. The anti-PRL an- 
tibodies, linked to the immunoreactive sites of 
PRL, were demonstrated by the immunoperox- 
idase technique [lo] using the peroxidase- 
antiperoxidase (PAP) reagent (PAP reagents; kit 
ref.4743 1, Biolyon). These reagents were designed 
for the visualization of specific antigens on 
histological sections but the recommended pro- 
cedure was unchanged. Peroxidase was then 
revealed for 10 min in a solution of 3,3 ‘-diamino- 
benzidine/dimethylformamide (0.5 mg/ml) and 
0.01% (v/v) H202. A brown-colored deposit 
developed at the immunoreactive sites. 
2.5. Affinity chromatography 
1 ml plasma samples were placed on a 2 ml col- 
umn of concanavalin A-Sepharose 4B (Pharmacia, 
Uppsala). The column was rinsed with 20 ml PBS, 
then eluted with 20 ml of 1 M methyl+D- 
glucopyranoside in PBS buffer. Elution was car- 
ried out at 0.2 ml/min and fractions of 2 ml were 
collected. The samples were 
munoassayed for PRL and 
described above. 
lyophilized, radioim- 
subjected to IPE as 
2.6. Degiycosylation experiments 
0.1 mg protein of glycosylated material (bound 
material eluted with glucopyranoside) was in- 
cubated for 24 h at 37°C in potassium phosphate 
buffer (pH 6.5) with 0.2 U endo H or 0.5 U endo 
F. Endo H and endo F were obtained from Boeh- 
ringer (Mannheim). Samples incubated with or 
without endo H or endo F were subjected to IPE 
as described above. 
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Fig. 1. Electrophoresis, electrotransfer and immunoper- 
oxidase revelation of the variants of PRL in human 
plasma. (A) Demonstration of the efficiency of the 
electrotransfer procedure. Plasma was loaded in two 
lanes of the slab. At the end of electrophoresis, one lane 
was stained and scanned (continuous line), the other 
submitted to electrotransfer and the remaining material 
stained and scanned (dashed line). After a 90 min 
transfer at 30 V, no proteins of c60 kDa remained in 
the gel and a transfer yield of 90% was obtained for 
human serum albumin (67 kDa). Arrowheads indicate 
positions of the marker proteins [l, bovine serum 
albumin (67 kDa); 2, egg albumin (45 kDa); 3, lysozyme 
(14.4 kDa)]. (B) Immunoperoxidase pattern of the 
variants of PRL. Dotted vertical lines indicate the 
position of PRL variants among plasma proteins. The 
PRL variants are not visible with Coomassie staining on 
account of their low plasma concentration. 
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3. RESULTS 
Fig.lA shows the electrophoretic mobilities of 
plasma proteins and demonstrates the efficiency of 
this new electrotransfer technique. By im- 
munoperoxidase revelation of the corresponding 
NC sheet, anti-hPRL allowed the immunostaining 
of two protein bands: a predominant band cor- 
responding to a 22 kDa form and a minor band 
corresponding to a 25 kDa form (fig.lB). A 
16 kDa form was also found which could corre- 
spond to the previously reported cleaved variant, 
isolated from normal and adenomatous pituitary 
tissue and from the plasma of pregnant women 
[l 11. Another minor 45 kDa form was sometimes 
observed but storage of the plasma at -20°C led 
to the total (or almost total) disappearance of this 
unstable form (unpublished). 
To determine whether these variants were 
glycosylated, plasma was filtered over con- 
canavalin A-Sepharose 4B and PRL immunoreac- 
tivity was measured in the elution volume. 21.0 + 
4.4% (n = 3) of the prolactin immunoreactivity 
was retained on the column and eluted in a second 
Fig.2. Revelation, using IPE, of PRL variants of human 
plasma (A), concanavalin A-unretained human plasma 
(B), concanavalin A-retained human plasma (C) and 
concanavalin A-retained human plasma after 
electrophoresis under non-dissociating conditions (D). 
step with 1 M methyl+D-glucopyranoside. Unre- 
tained (non-glycosylated material) and retained 
(glycosylated material) fractions were subjected to 
IPE. The 22 kDa band corresponded to non- 
glycosylated PRL (fig.2, lane B) and the 25 and 
16 kDa bands to GPRL (fig.2, lane C). When the 
glycosylated material was submitted to elec- 
trophoresis under nondissociating conditions 
(sample buffer without 2-mercaptoethanol, ab- 
sence of heating before the run), the 25 kDa form 
was not detected and was replaced by a larger 
variant of approx. 60 kDa (fig.2, lane D). 
To elucidate the structure of this glycocon- 
jugate, attempts were made to remove the car- 
bohydrate chains of PRL by incubation with 
specific endoglycosidases. In our hands, en- 
doglycosidase H failed to modify the elec- 
trophoretic mobility of the concanavalin 
( x 
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Fig.3. Attempts to deglycosylate GPRL. Concanavalin 
A-retained human plasma was incubated without (A) or 
with (B) endo F (0.5 U/O.1 mg protein) for 24 h at 37°C 
and subjected to IPE. 
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A-retained PRL (not shown). In contrast, the 
25 kDa form was almost completely changed into 
the 22 kDa form after incubation with en- 
doglycosidase F (fig.3). The electrophoretic 
mobility of the 16 kDa form was apparently not 
modified. 
4. DISCUSSION 
The IPE technique decsribed here is characteriz- 
ed by its extreme sensitivity. This technique was 
able to detect hPRL and an additional modified 
variant, without immunoprecipitation before elec- 
trophoresis, from the equivalent of 1 pl of our 
human plasma presenting a very high level of PRL. 
The apparent molecular mass of this variant is 
25 kDa and it could correspond to the un- 
characterized PRL variant detected in human 
plasma [3]. 
Affinity chromatography experiments indicate 
that this variant is a glycosylated form of the hor- 
mone. To some extent, this glycosylated hormone 
might be the circulating form of the 29 kDa com- 
ponent which has been detected in crude human 
pituitary homogenates [ 121. Furthermore, a similar 
glycosylated variant (25 kDa) was recently found 
in human amniotic fluid between weeks 32 and 40 
of normal pregnancy [4]. Shoupe et al. [13] ob- 
served only one 60 kDa hPRL-like substance in 
human plasma of pregnant patients that bound to 
concanavalin A. This variant ranged from 10 to 
30% of the total immunoassayable PRL. These 
authors isolated this glycosylated form by 
molecular sieve chromatography on Sephadex 
G-100 using a nondissociating buffer. Now, it is 
noteworthy that the electrophoresis of our 
glycosylated material under nondissociating condi- 
tions elicited such a 60 kDa band. This form might 
represent an aggregate of smaller molecules rather 
than the true circulating form of the glycosylated 
hormone in the plasma. Lastly, our results provide 
strong evidence for the existence of a cleaved 
glycosylated form (A& = 16000) of PRL in human 
plasma. This form was not shown among 
nonglycosylated material. 
In contrast with a previous report concerning 
ovine PRL [5], endo H failed to deglycosylate 
GhPRL in our experiments. Nevertheless, GhPRL 
was converted to the major form by digestion with 
endo F. As previously shown, endo F appears very 
similar in specificity to endo H [14], both 
hydrolyse N-glycans of the high-mannose type 
[ 14,151. The only discrepancy is that endo F 
cleaves the biantennary chain of an IgM glycopep- 
tide 1141. It may thus be inferred that the added 
carbohydrate is a high-mannose bi~tenn~y 
oligosaccharide. 
As an overall conclusion, using IPE, we have 
been able to demonstrate the presence of a 
glycosylated variant of PRL in human plasma, the 
deglycosylation of which can be achieved by in- 
cubation with endo F. If the biological role of this 
secreted variant is still unknown at present, the 
multifunctional nature of the PRL, ranging from 
growth promotion to inhibition of ovulation, 
could partly result from the existence of different 
forms of the hormone. 
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